Penny Stocks

Penny stocks are incredibly dangerous investments that can burn new and seasoned investors alike. InvestorPlace’s best micro-cap analysts recommend buying penny stocks, or cheap stocks, only with the strictest of warnings. But while pink sheet stocks can be halved in the blink of an eye, they can also double much quicker than large-cap stocks.

Trading on the Irony of Exela Technologies Could Be Risky

While the bulls may utterly hate those who are bearish on XELA stock, it’s the pessimists that really give shares their fuel.

7 Renewable Penny Stocks to Buy for a Climate-Focused World

Penny stocks are for the risk-tolerant, but these cheap plays are for the environmentally conscious investor as well.

7 of the Best Penny Stocks to Buy Coming Into Year-End

These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months.

6 of the Best Penny Stocks to Snap Up on Robinhood

Uncertainty due to inflation, geopolitical turmoil and the delta variant means it's time to check out these Robinhood penny stocks.

Despite Its Best Attempts, Naked Brands Is Unlikely to Recover

Things are unlikely to change much for NAKD stock, with several loopholes in Naked Brands' turnaround strategy at this time.

7 Reddit Penny Stocks Dazzling Investors with Low Floats

Penny stocks are incredibly risky. But if you must engage this sector, you certainly have a better chance with low-float securities.

The Moonshot Investor: Golden Rule Investing for Penny Stocks

Wall Street often overlooks penny stocks. Retail investors can use a winning strategy to get ahead of the curve and beat out hedge funds.

7 of the Best Penny Stocks for Any Portfolio

As the global economy recovers in fits and starts, one way to play the long-term expansion in global markets is with solid penny stocks.

Visit Camber Energy for the Meme Chatter, Stay for the ESG Patent

CEI stock might profit from a Reddit-fueled run-up, or because of an intriguing IP agreement. Either way, the stock's worth a look.

If at First Zomedica Doesn’t Succeed, It Tries, Tries Again

The launch of the Truforma diagnostic platform didn't go perfectly for Zomedica, but holders of ZOM stock still have reason for optimism.

7 Penny Stocks Waiting on the FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.

After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble

There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.

Naked Brands Is a Favorable Risk-to-Reward Trade

NAKD stock offers a good risk-to-reward trade for risk-seeking investors. The stock could soar upon a successful acquisition.

Sundial Growers Is Not Worth the Sum of All Its Parts

Add up all its investments and revenue streams and Sundial still isn’t worth $1.54 billion. Investors should pass on SNDL stock.

Sundial Growers Stock Looks as If It May Be Coming To Life Before Too Long

Past the headline weakness, there were some upbeat points in Sundial's latest earnings report. SNDL stock could be turning the corner here.

Naked Brand Could Rally Until Its Merger Plans Become Definitive

It's still not a sure thing, but some traders may want to buy NAKD stock before more details about its possible merger plans emerge.

Afghanistan Disaster Will Be a Headache for Sundial Growers

Although SNDL stock remains a “cheap” investment, it might stay that way due to political pressure affecting Washington.

Exela Stock Has All the Trappings of a Reddit Favorite

With a high short interest ratio and a tech-heavy operating model, XELA stock has all the makings of a potentially enticing Reddit favorite.

SOS Stock Is a Risky Mining Play For Leveraged Bitcoin Exposure

Chinese crypto mining play SOS stock has fallen off a cliff recently, but the stock is still good for those looking to scalp profits.

Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress

Atossa’s COVID-19 treatment is too little too late and I am concerned about the market size for Endoxiden. ATOS stock should not have a $448 million market cap.